Actively Recruiting
Maximal Use Trial of Ruxolitinib 1.5% Cream for Adults and Adolescents with Hidradenitis Suppurativa
Led by Incyte Corporation · Updated on 2026-10-09
24
Participants Needed
21
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the maximal use of ruxolitinib cream in adults and adolescents who have hidradenitis suppurativa, a chronic skin condition characterized by painful lumps. This Phase 1 interventional trial aims to study this topical treatment applied to affected skin areas to understand its safety and pharmacokinetics. Participants will apply ruxolitinib cream at a concentration of 1.5% twice daily as a thin film to affected skin areas. The study includes only one treatment group without a placebo, focusing on maximal use. The treatment period lasts up to 24 weeks, during which no other topical or systemic antibiotics for hidradenitis suppurativa will be used. During the study, participants will be regularly monitored for treatment-emergent adverse events and any events leading to interruption or discontinuation of the treatment. Researchers will also measure pharmacokinetic parameters such as peak concentration and drug exposure over time. Participants adherence to treatment and safety will be closely observed throughout the 24-week period.
CONDITIONS
Brief Title
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
Research Team
I
Incyte Corporation Call Center (US)
I
Incyte Corporation Call Center (ex-US)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here